Overview

This study is a prospective, open-label, single arm, multicenter study lasting 12 weeks to evaluate effectiveness and safety of lemborexant(LEM). Patient self-evaluation reports and safety events will be collected at baseline and 4 visits during treatment.

Eligibility

Inclusion Criteria:

• Adults (≥18 years) and agreed to participate in the study, regardless of gender.
• Diagnosed with insomnia according to DSM-5.
• Insomnia Severity Index (ISI) score >10.
• Subjects who can guarantee at least 7 hours of bedtime.
• Subjects signed informed consent forms after the prescription.

Exclusion Criteria:

• Beings unable to understand the questionnaire.
• PHQ-9 scores ≥ 20.
• GAD-7 scores ≥ 15.
• Suicidal thoughts/behaviors in the past one month or history of suicide, etc.
• Severe psychiatric disorder in the judgment of the investigator prevents completion of the trial.
• History of serious illness, mental illness, medication use, and uncontrolled poor sleep habits that the investigator believes interfere with the study evaluation or the safety of the subject.
• According to the precautions listed in the instructions, there are any contraindications or other conditions for which the use is prohibited (such as narcolepsy, severe liver damage, pregnant, nursing or pregnant women, etc.).
• Other conditions not considered appropriate for participation by clinicians.